ABCELLERA BIOLG (ABCL)
(Delayed Data from NSDQ)
$4.24 USD
-0.23 (-5.15%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $4.21 -0.03 (-0.71%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ABCL 4.24 -0.23(-5.15%)
Will ABCL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ABCL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABCL
AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Strength Seen in ABCELLERA BIOLG (ABCL): Can Its 15.0% Jump Turn into More Strength?
ABCL: What are Zacks experts saying now?
Zacks Private Portfolio Services
ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates
Other News for ABCL
AbCellera: Just Another Biotech Stock
Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday
AbCellera Biologics (ABCL) Receives Price Target Upgrade from KeyBanc | ABCL Stock News
AbCellera Biologics (ABCL) Rated Outperform by Leerink Partners | ABCL Stock News
AbCellera assumed with an Outperform at Leerink